# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HL...
The Companies intend to use the net proceeds from the sale of the Notes to repay a portion of their borrowings under the Credit...
Organon (NYSE:OGN) ("Organon"), a global healthcare company with a focus on women's health, announced today that it...
Goldman Sachs analyst Chris Shibutani maintains Organon (NYSE:OGN) with a Neutral and raises the price target from $18 to $20.
Goldman Sachs analyst Chris Shibutani maintains Organon (NYSE:OGN) with a Neutral and raises the price target from $18 to $20.
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
Organon (NYSE:OGN) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $0.93 by 31.18 p...